Big Pharma Continues Raking in Big Profits and Expectation-Beating Revenue Fueled by Egregious Pricing Practices and Anti-Competitive Tactics This week, several Big Pharma companies held earnings calls for the first quarter of the year touting revenue and profits beating Wall Street expectations fueled by price hikes and anti-competitive practices, including Novartis, Sanofi, Bristol Myers Squibb, […]
Two Reports Explore Cost for U.S. Patients and the U.S. Health Care System of Big Pharma’s Out-of-Control Prices on GLP-1s Two new analyses released Wednesday highlight how the egregious prices set by Big Pharma on GLP-1 weight loss drugs are unsustainable for U.S. patients and the U.S. health care system. The first analysis in the […]
Big Pharma Giant Kicks Off Q1 Earnings After Hiking Prices More Than 40 Times in 2023 This week, brand name drug giant Johnson & Johnson kicked off the first round of Big Pharma earnings calls for the first quarter of 2024. The company surpassed Wall Street analysts’ earnings expectations after hiking prescription drug prices more […]
Big Pharma’s Announcements Designed to Deflect from Criticism and Scrutiny for Years of Egregious Anti-Competitive and Pricing Practices on Brand Name Inhalers Under increasing scrutiny from policymakers and the public for egregious anti-competitive and price-gouging practices on brand name inhalers, several Big Pharma companies, including AstraZeneca, Boehringer Ingelheim and GlaxoSmithKline (GSK), recently announced commitments to […]
CBO Says Cost to Taxpayers of Covering GLP-1 Medications Would Outpace Savings from “Reducing Other Health Care Spending” In case you missed it, the Congressional Budget Office (CBO) recently predicted that covering GLP-1 weight loss drugs “at their current prices, would cost the federal government more than it would save from reducing other health care […]
Big Pharma Exec Downplays “Modest” Drug Pricing Solutions That CEO Previously Claimed Would Reduce R&D and Called “Gun to Your Head” Big Pharma can’t seem to keep its story straight. The pharmaceutical industry continues to accidentally debunk its own doom-and-gloom rhetoric insisting solutions to lower drug prices by holding brand name drug companies accountable will […]
Median Price Set by Brand Name Drug Makers on New Treatments Climbs to $300,000 In case you missed it, on Friday, Reuters released a new analysis which found that the median annual price among new drugs approved by the U.S. Food and Drug Administration (FDA) in 2023 reached $300,000. This number was 35 percent higher than the […]
GLP-1 Weight-Loss Leaders “Blow Past” Wall Street Projections in Q4 2023, Hike Prices on at Least 20 Brand Name Products in First Weeks of 2024 Big Pharma giants Eli Lilly and Novo Nordisk recently reported earnings that blew past Wall Street estimates for the fourth quarter of 2023. Both brand name companies have become leaders […]
More Big Pharma Giants Report Earnings That Top Wall Street Expectations While Continuing to Hike Prices on Dozens of Brand Name Drugs Merck, Bristol Myers Squibb, and AbbVie all recently reported earnings for the fourth quarter of 2023 that topped Wall Street analysts’ expectations after all three Big Pharma giants engaged in price hikes in […]
Patent Abuse Designed to Extend Monopolies, Block Competition and Keep Prices High Takes Center Stage at HELP Committee Hearing On Thursday, the U.S. Senate Committee on Health, Education, Labor and Pensions (HELP) held a hearing with the CEOs of three Big Pharma giants: Johnson & Johnson, Merck and Bristol Myers Squibb. During the hearing, lawmakers, […]